The male carriers of MLH1 or MSH2, MLH1, and MSH2 germline mutations had a HR of 23.2 (95% CI = 9.2–58.2), 24.2 (95% CI = 9.8–60.1), and 38.2 (95% CI = 12.2–119.9) for CRC compared to male non-mutation carriers, respectively. Here, MSH2 is linked to colorectal carcinoma.